Aminobenzoic acid injection

This product is a procoagulant. There are various natural antagonists of plasmin (pro) in the blood circulation, such as antiplasmin. Under normal circumstances, the activity of antifibrinolytic substances in the blood is many times higher than that of fibrinolytic substances, so fibrinolytic bleeding will not occur. However, these antagonists cannot block the activation of activators (such as urokinase, etc.) adsorbed on the fibrin network to form plasmin. Plasmin is a peptide chain endonuclease that can cleave the arginine and lysine peptide chains of fibrin (pro) in a neutral environment to form fibrin degradation products and cause blood clots to dissolve and bleed. Plasminogen specifically adsorbs on fibrin through the lysine binding site in its molecular structure, and lysine can competitively inhibit this adsorption, reduce the adsorption rate of plasminogen, and thus reduce the degree of plasminogen activation to reduce bleeding. The stereo configuration of this product is similar to lysine (1,5-diaminohexanoic acid), which can competitively inhibit the adsorption of plasminogen on the fibrin network, thereby preventing its activation and protecting fibrin from being degraded by plasmin to achieve a hemostatic effect.

The main ingredient of this product and its chemical name is: p-aminomethylbenzoic acid monohydrate. Molecular formula: C8H9NO2H2OMolecular weight: 169.18

This product is a colorless, clear liquid.

This product is mainly used for bleeding caused by excessive primary fibrinolysis, including acute and chronic, localized, or systemic hyperfibrinolytic bleeding. The latter is common in cancer, leukemia, gynecological accidents, severe liver disease bleeding, etc.

Intravenous injection or drip: 0.1-0.3g each time, not more than 0.6g per day.

Compared with 6-aminocaproic acid, this product has 5 times stronger antifibrinolytic activity. Adverse reactions are extremely rare. No thrombosis has been observed in long-term use, but dizziness, headache, and pupil discomfort may occur occasionally. Patients with a tendency to myocardial infarction should use it with caution.

It is contraindicated for those who are allergic to this product.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: This experiment has not been conducted and there is no reliable reference. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.

It is incompatible with thrombolytic agents such as penicillin or urokinase; the combined use of oral contraceptives, estrogens or prothrombin complex concentrates with this product may increase the risk of thrombosis.

Keep tightly closed.

10ml:0.1g

36 months

Jiangsu Langou Pharmaceutical Co., Ltd.

• Founded in:

  2013-06-21

• Address:

  No. 1, Langou Road, Xuzhou Industrial Park, Jiangsu

• Tax NO.:

  91320305071075704T

• Registered Funds:

  100 million yuan

• Email:

  Log in to view